

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

CHANGE OF CHIEF FINANCIAL OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) hereby announces that Ms. Cao Xiaochun (曹曉春) (“**Ms. Cao**”) has tendered her resignation as the chief financial officer of the Company (the “**Chief Financial Officer**”) with effect from October 21, 2022 so that she can devote more time to serve the Board and focus on the work as a general manager.

Ms. Cao will remain as executive Director and general manager of the Company, and she has confirmed that she has no disagreement with the Board and there is no matter that needs to be brought to the attention of the holders of securities of the Company in respect of her resignation as the Chief Financial Officer.

The Board is pleased to announce that Ms. Yang Chengcheng (楊成成) (“**Ms. Yang**”) has been appointed as the Chief Financial Officer with effect from October 21, 2022.

The biography of Ms. Yang is set out below:

Ms. Yang, aged 48, joined the Company in September 2022. Prior to joining the Company, she had worked in management positions such as senior auditor of PricewaterhouseCoopers, assistant financial controller of Otis Electric Elevator Co., Ltd. (奧的斯機電電梯有限公司) (formerly known as Hangzhou Xizi Otis Co., Ltd. (杭州西子奧的斯股份有限公司)), financial controller of Xizi Elevator Group Co., Ltd. (西子電梯集團有限公司), director, financial controller and investment officer of Baida Group Co., Ltd. (百大集團股份有限公司) (its shares are listed on the Shanghai Stock Exchange, stock code: 600865), financial controller of Pacific Shuanglin Biopharmacy Co., Ltd. (派斯雙林生物製藥股份有限公司) and managing director, financial controller and person-in-charge of risk control and post investment of Zhejiang United Investment Group Co., Ltd. (浙江民營企業聯合投資股份有限公司). Ms. Yang is familiar with domestic and overseas accounting and taxation standards and specializes in finance, taxation, risk control and operation management. She has over 20 years of experience in financial management as well as investment and financing and capital operation of listed companies. Ms. Yang holds a master's degree of business administration from Zhejiang University.

The Board would like to take this opportunity to express its gratitude to Ms. Cao for her valuable contribution to the Company during her tenure of service as the Chief Financial Officer and welcome Ms. Yang to the new appointment.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 21, 2022

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive Directors are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.